AbCellera Biologics Inc. (ABCL)
| Market Cap | 1.53B +103.1% |
| Revenue (ttm) | 75.13M +160.6% |
| Net Income | -146.41M |
| EPS | -0.49 |
| Shares Out | 303.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,629,404 |
| Open | 4.90 |
| Previous Close | 4.82 |
| Day's Range | 4.88 - 5.18 |
| 52-Week Range | 1.94 - 6.52 |
| Beta | 1.03 |
| Analysts | Strong Buy |
| Price Target | 8.17 (+61.78%) |
| Earnings Date | May 11, 2026 |
About ABCL
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lil... [Read more]
Financial Performance
In 2025, AbCellera Biologics's revenue was $75.13 million, an increase of 160.56% compared to the previous year's $28.83 million. Losses were -$146.41 million, -10.10% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ABCL stock is "Strong Buy." The 12-month stock price target is $8.17, which is an increase of 61.78% from the latest price.
News
AbCellera to Present at Upcoming Investor Conferences in May and June 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in May and June 2026.
AbCellera initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of AbCellera (ABCL) with an Overweight rating and $7 price target
AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
The company has transitioned from a partnership-driven model to advancing its own pipeline, with a focus on challenging antibody targets and a strong liquidity position. Lead asset ABCL635 targets hot flashes in menopausal women, with key phase II data expected in Q3 and potential expansion into oncology-related indications.
AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call.
AbCellera initiated with a Buy at JonesResearch
JonesResearch analyst Debanjana Chatterjee initiated coverage of AbCellera (ABCL) with a Buy rating and $11 price target AbCellera’s validated antibody discovery platform has advanced 19 molecules int...
AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026.
AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
A robust antibody-based drug discovery platform supports a growing pipeline, with lead asset ABCL635 in phase II targeting menopausal hot flashes and potential expansion to cancer therapy-induced symptoms. In-house manufacturing and strong financial backing enable flexibility and sustained development.
AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference
The company has evolved into a biotech with robust antibody discovery and manufacturing capabilities, advancing a pipeline led by ABCL635 for menopausal VMS, which is differentiated by safety and dosing convenience. Phase II data for ABCL635 is expected in Q3, with rapid expansion into oncology and additional assets progressing toward clinical trials.
AbCellera Biologics Earnings Call Transcript: Q4 2025
Transitioned to a clinical-stage biotech, expanded pipeline to four clinical/IND-enabling programs, and ended 2025 with $700M liquidity. Revenue rose to $75M, net loss narrowed to $146M, and key clinical readouts are expected in 2026.
AbCellera reports FY25 EPS (49c) vs. (55c) last year
Reports FY25 revenue $75.1M vs. $28.8M last year. “In 2025, AbCellera (ABCL) successfully delivered on all its corporate priorities, transitioned to a clinical-stage biotech company, and ended the yea...
AbCellera Reports Full Year 2025 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2025 Business Results.
AbCellera to Present at Upcoming Investor Conferences in March and April 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in March and April 2026.
AbCellera to Report Full Year 2025 Financial Results on February 24, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Full Year 2025 Financial Results on February 24, 2026.
AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company has transitioned to a clinical-stage model, advancing a robust pipeline led by ABCL635 for menopause symptoms, with key data readouts expected in 2025. Strong liquidity, a new GMP facility, and a focus on differentiated, high-need indications position it for late-stage clinical expansion.
AbCellera doses first patients in Phase 2 portion of ABCL635 trial
AbCellera (ABCL) announced that the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635, a potential treatment for vasomotor symptoms
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of VMS Due to Menopause...
AbCellera to receive $36M upfront in patent litigation settlement with Bruker
AbCellera (ABCL) announced that it has entered into a settlement and patent license agreement with Bruker Corporation (BRKR), resolving the patent litigation between the two companies globally. As par...
AbCellera and Bruker Reach Global Settlement of Patent Litigation
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera and Bruker Reach Global Settlement of Patent Litigation.
AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference
Transitioning to a clinical-stage biotech, the company now prioritizes internal drug development, highlighted by advanced programs in menopause and atopic dermatitis. Strong liquidity and end-to-end capabilities support a robust pipeline, with over 20 assets in development.
AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference
The company has completed its transition to developing proprietary clinical assets, with two wholly owned drugs in the clinic and a third in IND-enabling studies. ABCL635 targets a large unmet need in menopausal hot flashes, with proof-of-concept data expected in 2025. Liquidity exceeds CAD 700 million, supporting at least three years of operations.
AbCellera Appoints Dr. Stephen Quake to its Board of Directors
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Stephen Quake to its Board of Directors.
AbCellera downgraded to Market Perform from Outperform at Leerink
Leerink downgraded AbCellera (ABCL) to Market Perform from Outperform with a $4 price target
AbCellera Biologics Earnings Call Transcript: Q3 2025
Transitioned to a clinical-stage biotech with two phase I trials underway and strong liquidity of $680M. Revenue rose to $9M, but net loss widened to $57M as R&D investment increased. Confident in advancing pipeline and maintaining funding for over three years.
AbCellera Reports Q3 2025 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2025 Business Results.